Growth Hormone Secretagogue

Ipamorelin

A selective growth hormone secretagogue peptide that stimulates GH release from the pituitary with the highest selectivity of any GHRP - without raising cortisol, prolactin, or ACTH. The cleanest GH-stimulating peptide available, typically paired with a GHRH analogue (CJC-1295) for synergistic GH pulse amplification.

recoveryperformancesleepanti-aging
Tier BGenerally safe — moderate evidence
Evidence gradeCAnimal studies / Case reports
JS

Reviewed & fact-checked by

Dr. Jane Smith, MD, PhD

Chief Medical Reviewer · Last updated: March 25, 2026

Verified

Why Ipamorelin Is the Preferred GHRP

The GHRP (Growth Hormone Releasing Peptide) class includes several compounds: GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. All stimulate GH release, but with significantly different side effect profiles.

GHRP-2 and GHRP-6 elevate cortisol and prolactin alongside GH. Hexarelin desensitises receptors rapidly and strongly elevates cortisol. Ipamorelin is the exception: it produces selective GH stimulation without significant cortisol, prolactin, or ACTH elevation. This selectivity profile makes it the preferred choice for non-clinical use.

Mechanism of Action

Ipamorelin is a pentapeptide that mimics ghrelin (the hunger hormone) at the growth hormone secretagogue receptor (GHSR-1a) in the pituitary. Unlike ghrelin, which has broad systemic effects, Ipamorelin is highly selective for the pituitary GHSR with minimal cross-reactivity at other receptor types.

GHSR activation triggers GH release through IP3-mediated calcium mobilisation in somatotroph cells. The resulting GH pulse is physiologically normal in shape and duration - it mirrors the GH pulses that naturally occur during deep sleep, rather than producing the sustained supraphysiological GH elevation seen with exogenous HGH.

The Ipamorelin + CJC-1295 Protocol

The most established GHRP/GHRH combination. The rationale is straightforward:

  • GHRH (mimicked by CJC-1295) tells the pituitary to prepare and release GH
  • GHRP (Ipamorelin) tells the pituitary to amplify that release via GHSR activation

Activating both receptor pathways simultaneously produces synergistic GH pulse amplification 3-5x greater than either peptide alone. This is the biochemical basis for combining the two classes.

Standard protocol: 100-200mcg Ipamorelin + 100mcg CJC-1295 (no DAC), injected subcutaneously 30-60 minutes before sleep, fasted.

Sleep Timing Is Critical

Growth hormone is predominantly secreted during slow-wave sleep, with the largest pulse occurring in the first 90 minutes of sleep onset. Injecting Ipamorelin + CJC-1295 30-60 minutes before sleep amplifies this natural pulse at its physiologically correct timing - producing GH elevation during the sleep window when the body is already programmed to use it for tissue repair and cellular regeneration.

Stacking Interactions

How Ipamorelin interacts with other compounds

+
CJC-1295Synergisticmoderate evidence

The standard GH optimisation stack. Inject both simultaneously before sleep. Most practitioners use 100-200mcg of each.

+
BPC-157Synergisticweak evidence

BPC-157 upregulates GH receptors in tissues. Ipamorelin increases circulating GH levels. BPC-157 makes target tissues more responsive to the GH that Ipamorelin produces.

Safety Profile — Tier B

Generally safe — moderate evidence

Contraindications

  • Active cancer or cancer history - GH promotes IGF-1 which is mitogenic
  • Diabetic retinopathy
  • Pregnancy
  • Competitive athletes - WADA prohibited substance

Side Effects

  • Mild water retention in first 2 weeks (resolves)
  • Increased appetite - common and dose-dependent
  • Mild headache in some users
  • Flushing immediately post-injection
  • Tingling or numbness (carpal tunnel symptoms) at high doses

Drug Interactions

Insulin - GH increases insulin resistance; monitor glucoseCorticosteroids - reduce GH responseThyroid medications - GH secretagogues may alter thyroid hormone metabolism

Research References

  1. [1]PubMed: 9849822
  2. [2]PubMed: 10202645